The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement - PubMed (original) (raw)
Review
doi: 10.1189/jlb.1103586. Epub 2004 Mar 2.
Affiliations
- PMID: 14996827
- DOI: 10.1189/jlb.1103586
Review
The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement
Andrew D Weinberg et al. J Leukoc Biol. 2004 Jun.
Abstract
OX40 (CD134), a membrane-bound member of the tumor necrosis factor-receptor superfamily, is expressed primarily on activated CD4(+) T cells. Following engagement on the cell surface, OX40 delivers a costimulatory signal that leads to potent, proinflammatory effects. Engagement of OX40 during antigen (Ag)-specific stimulation of T cells leads to increased production of memory T cells, increased migration of Ag-specific T cells, enhanced cytokine production by effector T cells, and the ability to break peripheral T cell tolerance in vivo. Therefore, OX40 engagement in vivo could have important ramifications for the enhancement of vaccine strategies and inhibition of unwanted inflammation. This review summarizes the molecular and cellular events that occur following OX40 engagement during Ag-specific T cell activation.
Similar articles
- OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.
Huddleston CA, Weinberg AD, Parker DC. Huddleston CA, et al. Eur J Immunol. 2006 May;36(5):1093-103. doi: 10.1002/eji.200535637. Eur J Immunol. 2006. PMID: 16541471 - Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE, Redmond WL, Haley D, Weinberg AD. Ruby CE, et al. Eur J Immunol. 2007 Jan;37(1):157-66. doi: 10.1002/eji.200636428. Eur J Immunol. 2007. PMID: 17183611 - Regulation of CD4 T cell memory by OX40 (CD134).
Salek-Ardakani S, Croft M. Salek-Ardakani S, et al. Vaccine. 2006 Feb 13;24(7):872-83. doi: 10.1016/j.vaccine.2005.07.108. Epub 2005 Sep 7. Vaccine. 2006. PMID: 16176850 Review. - OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N, Takahashi T, Soroosh P, Sugamura K. Ishii N, et al. Adv Immunol. 2010;105:63-98. doi: 10.1016/S0065-2776(10)05003-0. Adv Immunol. 2010. PMID: 20510730 Review. - Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y, Akiba H, Takeda K, Atsuta M, Yagita H, Okumura K. Satake Y, et al. Biochem Biophys Res Commun. 2000 Apr 21;270(3):1041-8. doi: 10.1006/bbrc.2000.2560. Biochem Biophys Res Commun. 2000. PMID: 10772947
Cited by
- High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
Ramser M, Eichelberger S, Däster S, Weixler B, Kraljević M, Mechera R, Tampakis A, Delko T, Güth U, Stadlmann S, Terracciano L, Droeser RA, Singer G. Ramser M, et al. BMC Cancer. 2018 Apr 16;18(1):425. doi: 10.1186/s12885-018-4339-0. BMC Cancer. 2018. PMID: 29661166 Free PMC article. - K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G. Caruana I, et al. Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17. Clin Cancer Res. 2015. PMID: 25691731 Free PMC article. - Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis.
Zhou YB, Ye RG, Li YJ, Xie CM. Zhou YB, et al. Rheumatol Int. 2009 Feb;29(4):417-25. doi: 10.1007/s00296-008-0697-2. Epub 2008 Sep 20. Rheumatol Int. 2009. PMID: 18802705 - TNF superfamily: costimulation and clinical applications.
Vinay DS, Kwon BS. Vinay DS, et al. Cell Biol Int. 2009 Apr;33(4):453-65. doi: 10.1016/j.cellbi.2009.02.001. Epub 2009 Feb 20. Cell Biol Int. 2009. PMID: 19230849 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials